key: cord-0902084-t5iz3vdz
authors: Sheahan, Timothy P.; Sims, Amy C.; Zhou, Shuntai; Graham, Rachel L.; Hill, Collin S.; Leist, Sarah R.; Schäfer, Alexandra; Dinnon, Kenneth H.; Montgomery, Stephanie A.; Agostini, Maria L.; Pruijssers, Andrea J.; Chapell, James D.; Brown, Ariane J.; Bluemling, Gregory R.; Natchus, Michael G.; Saindane, Manohar; Kolykhalov, Alexander A.; Painter, George; Harcourt, Jennifer; Tamin, Azaibi; Thornburg, Natalie J.; Swanstrom, Ronald; Denison, Mark R.; Baric, Ralph S.
title: An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus
date: 2020-03-20
journal: bioRxiv
DOI: 10.1101/2020.03.19.997890
sha: 4a1213360996a18ae85d69618789e5daaa739e94
doc_id: 902084
cord_uid: t5iz3vdz

Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2. Herein, we show that the ribonucleoside analog β-D-N4-hydroxycytidine (NHC, EIDD-1931) has broad spectrum antiviral activity against SARS-CoV 2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC-prodrug (b-D-N4-hydroxycytidine-5’-isopropyl ester), improved pulmonary function, and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral but not host cell RNA, supporting a mechanism of lethal mutagenesis. The potency of NHC/EIDD-2801 against multiple coronaviruses, its therapeutic efficacy, and oral bioavailability in vivo, all highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.

The genetically diverse Orthocoronavirinae (coronavirus, CoV) family circulates 45 in many avian and mammalian species. Phylogenetically, CoVs are divided into 4 46 genera: alpha (group 1), beta (group 2), gamma (group 3) and delta (group 4). Three 47 expressing nanoluciferase (MERS-nLUC) 15 , we measured virus replication in cultures 94 exposed to a dose range of drug for 48hr. NHC was potently antiviral with an average 95 half-maximum effective concentration (IC50) of 0.15µM and no observed cytoxicity in 96 similarly treated uninfected cultures across the dose range (50% cytotoxic 97 concentration, CC50, >10µM) (Fig. 1A) . The therapeutic index for NHC was >100. 98

Similarly, NHC strongly inhibited SARS-CoV-2 replication in Vero cells with an IC50 of 99 CoV RdRp 20 (Fig. 2B) . The core of the RdRp molecule and main structural motifs that all 125

RdRp harbor ( Fig. 2B and Supplementary Figure 2 ) are highly conserved among CoV 126 including SARS-CoV-2. We previously reported that CoV resistance to another broad 127 spectrum nucleoside analog, remdesivir (RDV) was mediated by RdRp residues F480L 128 and V557L in a model coronavirus mouse hepatitis virus (MHV) and in SARS-CoV, 129 resulting in a 5-fold shift in IC50 (Fig. 2C) 21 . Consequently, we tested whether RDV 130 resistance mutations in MHV conferred cross resistance to NHC ( Figure 2D ). In fact, 131 the two RDV resistance mutations, alone or together conferred increased sensitivity to 132 inhibition by NHC. As our previous studies have demonstrated a high genetic barrier to 133 NHC for VEEV, influenza and coronavirus 11-13 , the lack of cross resistance further 134

suggests that NHC and RDV may select for exclusive and mutually sensitizing 135 resistance pathways. 136

To explore the breadth of antiviral efficacy against zoonotic CoV, we performed 137 antiviral assays in HAE with three zoonotic Bat-CoV, SHC014, HKU3 and HKU5. 138

Closely related to the beta 2b SARS-CoV, Bat-CoV SHC014 is capable of replicating in 139 human cells without adaptation 8 suggesting its potential for zoonotic emergence. More 140 distantly related SARS-like beta 2b CoV, recombinant Bat-CoV HKU3 has a modified 141 receptor binding domain to facilitate growth in cell culture 22 . Lastly, Bat-CoV HKU5 is a 142 MERS-like beta 2c CoV 23 . NHC diminished infectious virus production and the levels of 143 genomic/subgenomic viral RNA in HAE in a dose-dependent manner for all three Bat-144 CoVs (Fig. 3) . Therefore, the antiviral activity of NHC was not limited by natural amino 145 acid variation in the RdRp, which among the group 2b and group 2c CoV can vary by 146 almost 20% ( Fig. 2A) . Moreover, these data suggest that if another SARS-or MERS-147 like virus were to spillover into humans in the future, they would likely be susceptible to 148 the antiviral activity of NHC. 149 150 NHC antiviral activity is associated with increased viral mutation rates. 151

It has recently been shown that NHC treatment increases the mutation rate in 152 viral genomic RNA of RSV 24 , VEEV 11 , influenza 24 , and our previous study used RNA 153 seq to show that overall transition mutation frequency is increased during NHC 154 treatment of MHV and MERS-CoV during infection in continuous cell lines 13 . We sought to determine if NHC would increase the mutation frequency during MERS-CoV infection 156 in human primary human airway epithelial cells (HAE). Using MERS-CoV infected HAE 157 treated with either vehicle or a dose range of NHC or RDV, we show that both drugs 158 reduced virus titers in a dose-dependent manner (Fig. 4A) . We then employed a highly-159 sensitive high-fidelity deep sequencing approach (Primer ID NGS), which uses 160 barcoded degenerate primers and Illumina indexed libraries to determine accurate 161 mutation rates after antiviral treatment on viral RNA production 25 . Using this approach, 162 we analyzed a 538bp region of viral genomic RNA in nonstructural protein 15 (nsp15). 163

The error rates (#mutations/10,000 bases) in vehicle (0.01) or RDV (0.01) treated 164 cultures were very low. RDV is reported to act via chain termination of nascent viral 165 RNA, and thus the low error rates in RDV-treated cultures are in line with the proposed 166 MOA 26 . In contrast, the error rate was significantly increased in NHC-treated CoV RNA in a dose-dependent manner (10-fold at 10µM and 5-fold at 1µM) at both 24 168 and 48hpi (Fig. 4C ). The magnitude of the error rate in NHC-treated cultures correlated 169 with virus titer reduction. At 48hpi the respective error rate and virus titer was 0.015 and 170 3.96E+06 pfu/mL for vehicle treatment, 0.045 and 2.86E+04 pfu/mL with 1µM NHC; and 171 0.090 and 1.5E+02 pfu/mL 10µM NHC. Thus, with 1µM NHC a 3-fold increase in error 172 rate resulted in a 138-fold decrease in virus titer, while with 10µM NHC a 6-fold increase 173 in error rate resulted in a 26,000-fold decrease in virus titer. 174

We then examined the mutational spectra induced by NHC, which can be 175 incorporated into viral RNA as a substitution for either cytosine (C) or Uridine (U). RNA-176 mutagenic antivirals may incorporate in both nascent negative and positive sense RNA 177 during genome replication (Fig. 4D) . Adenine-to-guanine (A-to-G) and uracil-to-cytosine 178 (U-to-C) transitions were enriched in MERS-CoV genomic RNA in an NHC dose-179 dependent manner (Fig. 4E) . Collectively, these data used high-fidelity sequence 180 analysis to demonstrate a specific enrichment for A:G and C:U transitions in MERS-181

CoV RNA after NHC treatment of primary HAE cell cultures. 182 183 Therapeutic EIDD-2801 reduces SARS-CoV replication and pathogenesis. 184

Given the promising antiviral activity of NHC in vitro, we next evaluated its in vivo 185 efficacy using EIDD-2801, an orally bioavailable prodrug of NHC (b-D-N 4 -hydroxycytidine-5'-isopropyl ester), designed for improved in vivo pharmacokinetics and 187 oral bioavailability in humans and non-human primates 12 . Importantly, the plasma 188 profiles of NHC and EIDD-2801 were similar in mice following oral delivery 12 . We first 189 performed a prophylactic dose escalation study in C57BL/6 mice where we orally 190 administered vehicle (10% PEG, 2.5% Cremophor RH40 in water) or 50, 150 or 500 191 mg/kg EIDD-2801 2hr prior to intranasal infection with 5E+04 PFU of mouse-adapted 192 SARS-CoV (SARS-MA15), and then every 12hr thereafter. Beginning on 3dpi and 193 through the end of the study, body weight loss compared to vehicle treatment was 194 significantly diminished (50mg/kg) or prevented (150, 500mg/kg) with EIDD-2801 195 prophylaxis (P < 0.0001) (Supplemental Figure 2A) . Lung hemorrhage was also 196 significantly reduced 5dpi with 500mg/kg EIDD-2801 treatment (Supplemental Figure  197 2B). Interestingly, there was a dose-dependent reduction in SARS-CoV lung titer 198 (median titers: 50mg/kg = 7E+03 pfu/mL, 150mg/kg = 2.5E+03 pfu/mL, 500mg/kg = 50 199 pfu/mL, vehicle = 6.5E+04 pfu/mL) with significant differences among the vehicle, 150 200 mg/kg (P = 0.03) and 500mg/kg (P = 0.006) groups. Thus, prophylactic orally 201 administered EIDD-2801 was robustly antiviral and able to prevent SARS-CoV 202 replication and disease. 203

Since only the 500mg/kg group significantly diminished weight loss, hemorrhage 204 and reduced lung titer to near undetectable levels, we tested this dose under 205 therapeutic treatment conditions to determine if EIDD-2801 could improve the outcomes 206 of an ongoing CoV infection. As a control, we initiated oral vehicle or EIDD-2801 2hr 207 prior to infection with 1E+04 pfu SARS-MA15. For therapeutic conditions, we initiated 208 EIDD-2801 treatment 12, 24, or 48hr after infection. After initiating treatment, dosing for 209 all groups was performed every 12hr for the duration of the study. Both prophylactic 210 treatment initiated 2hr prior to infection and therapeutic treatment initiated 12hr after 211 infection significantly prevented body weight loss following SARS-CoV infection on 2dpi 212 and thereafter (-2hr: P = 0.0002 to <0.0001; +12hr: P = 0.0289 to <0.0001) (Fig. 5A) . 213

Treatment initiated 24hpi also significantly reduced body weight loss (3-5dpi, P = 0.01 to 214 <0.0001) although not to the same degree as the earlier treatment initiation groups. 215

When initiated 48hpi, body weight loss was only different from vehicle on 4dpi (P = 216 0.037, Fig. 5A ). Therapeutic EIDD-2801 significantly reduced lung hemorrhage when initiated up to 24hr after infection mirroring the body weight loss phenotypes (Fig. 5B) . 218

Interestingly, all EIDD-2801 treated mice had significantly reduced viral loads in the 219 lungs even in the +48hr group (Fig. 5C) , which experienced the least protection from 220 body weight loss and lung hemorrhage. We also measured pulmonary function via 221 whole body plethysmography (WPB). In Figure 5D , we show the WBP PenH metric, 222 which is a surrogate marker for bronchoconstriction or pulmonary obstruction 27 , was 223 significantly improved throughout the course of the study if treatment was initiated up to 224 12hr after infection, although the +24hr group showed sporadic improvement as well 225 (Fig. 5D ). Lastly, we blindly evaluated hematoxylin and eosin stained lung tissue 226 sections for histological features of ALI using two different and complementary scoring 227 tools 15 , which show that treatment initiated up to +12hr significantly reduced ALI ( indicating that neither vehicle nor drug treatment significantly affected the levels of or 278 mutated ISG15 mRNA transcripts (Fig. 6G ). Similar to our TCS data in Figure 6G , the total error rate in viral nsp10 was significantly increased in groups where treatment was 280 initiated prior to (-2hr, median error rate = 10.5 errors/10,000 bases, P < 0.0001) and up 281 to 24hr post infection (12hr, median error rate = 8.2 errors/10,000 bases, P < 0.0001 ; 282 +24hr, median error rate = 5.4 errors/10,000 bases, P = 0.0003) but the error rates in 283 ISG15 remained at baseline for all groups (Fig. 6H ). In addition, nucleotide transitions 284 observed in MERS-CoV genomes in vitro (i.e. C to U transitions, Fig. 3 ), were also 285 observed in vivo in groups where treatment was initiated prior to and up to 12hr post 286 infection (P = 0.0003 to < 0.0001) (Fig. 5I) . Importantly, these transitions were not 287 observed in host ISG15 mRNA (Fig. 5I) compressed as compared to that in humans. While SARS-and MERS-CoV lung titers 325 peak on 2dpi in mice concurrent with the onset of clinical signs and notable damage to 326 the lung epithelium, in humans this occurs 7-10 days after the onset of 327 symptoms 16,28,36,37 . Thus, in mice, the window within which to treat emerging CoV 328 infection prior to peak replication is compressed (e.g., 24-48hr) but should be much 329 longer in humans. Although speculative, the SARS-and MERS-CoV in vivo data 330 provided herein suggest that 2019-nCoV will prove highly vulnerable to NHC treatment 331 modalities in vivo, critical experiments that must be performed as animal models 332 become available. The data provided in this manuscript suggest that NHC should be 333 quickly evaluated in primate models of human disease, using immediate models for 334

Small molecule antivirals can exert their antiviral effect through multiple 336 mechanisms including blocking viral entry, inhibiting a virally encoded enzyme, blocking 337 virus particle formation, or targeting a host factor required for replication 40 . For VEE, 338 EIDD-2801 exerts its antiviral activity on the RNA-dependent RNA polymerase leading 339 to error catastrophe by inducing an error rate of replication that surpasses the error 340 threshold allowed to sustain a virus population 11,12 . This process occurs when NHC is incorporated during RNA synthesis then subsequently misread thus increasing mutation 342 rates. Therefore, the NHC MOA would appear less likely to be affected by the RNA 343 proofreading activity encoded by the nsp14 exonuclease function that otherwise limits 344 misincorperation 41 . Here, we present data using Primer ID NGS, a state of the art deep 345 sequencing-based approach, to quantitate the frequency and identity of the mutational 346 spectra in the MERS-CoV genome in both drug treated primary human airway cells and 347 in mice at single genome resolution 25 . As CoV are positive sense RNA viruses that 348 replicate through a negative sense RNA intermediate, NHC incorporation as a "C" or a 349 "U" can occur in both polarities of RNA. Using Primer ID NGS, we found increased 350 nucleotide transitions (A to G, G to A, C to U, U to C) consistent with those reported 351 after influenza and VEE infections 11,12 . Under identical conditions, remdesivir did not 352 alter the mutation rate in MERS-CoV genomic RNA, supporting its reported mechanism 353 of action as a chain terminator of viral RNA synthesis 26 . In primary human lung cell 354 cultures and mice infected with MERS-CoV, the NHC mutation rates inversely 355 correlated with a reduction in infectious virus. In addition, we found a positive correlation 356 between increased mutation rates and the frequency of nonsynonymous mutations and 357 the degree of therapeutic efficacy in mice. To explore the potential off-target effect in 358 host mRNA which may contribute to drug toxicity, we also examined the impact of NHC 359 treatment on transcripts from the highly MERS-CoV induced interferon stimulated gene 360 15 (ISG15). While ISG15 is present in great abundance, an accumulation of mutations 361 was not observed in ISG15 in this model even at 500mg/kg dosing. These data also 362 support previous studies using RNAseq to demonstrate that the model coronavirus 363 MHV displayed increased mutation frequencies following NHC treatment in vitro 13 . All 364 together, these data strongly support the notion that EIDD-2801 and its active 365 there was any NHC induced cytotoxicity, Calu3 2B4 cells were plated and treated with 418 NHC only as described above. Cells were exposed to the same ten-point dilution series 419 created for the in vitro efficacy studies. As above, 0.05% DMSO-treated cells served as 420 our 0% cytotoxicity control. Wells without cells served as our 100% cytotoxic positive 421 control. After 48hr, cell viability was measured on a Spectramax (Molecular Devices) via 422 function by whole body plethysmography was measured daily. On 5dpi, animals were 492 sacrificed by isoflurane overdose, lungs were scored for lung hemorrhage, and the 493 inferior right lobe was frozen at −80°C for viral titration via plaque assay. Briefly, 500,000 Vero E6 cells/well were seeded in 6-well plates. The following day, medium 495 was removed and serial dilutions of clarified lung homogenate were added per plate (10 -496 1 to 10 -6 dilutions) and incubated at 37˚C for 1hr after which wells were overlayed with 497 1X DMEM, 5% Fetal Clone 2 serum, 1X antibiotic/antimycotic, 0.8% agarose. Two days 498 after, plaques were enumerated to generate a plaque/ml value. Lung hemorrhage is a 499 gross pathological phenotype readily observed by the naked eye driven by the degree 500 of virus replication where the coloration of the lung changes from pink to dark red 48,49 . 501

The large left lobe was placed in 10 % buffered formalin and stored at 4°C for 1-3 502 prophylactic studies. The numbers of mice per group for the SARS-CoV studies were as 522 follows: Vehicle (n = 10), -2hr (n = 10), +12hr (n = 10), +24hr (n = 10), +48hr (n = 10). 523

The numbers of mice per group for the MERS-CoV therapeutic studies were as follows: 524

Vehicle (n = 9), -2hr (n = 9), +12hr (n = 9), +24hr (n = 7), +48hr (n = 10). As described above, each day mouse body weight and pulmonary function was quantitated. On 5dpi 526 for SARS-CoV and 6dpi for MERS-CoV, animals were humanely sacrificed and tissues 527 were harvested and analyzed as described above. In addition, for the MERS-CoV study, 528 lung tissue was harvested and stored in RNAlater (Thermo Fisher) at -80˚C and then 529 thawed, homogenized in Trizol reagent (Invitrogen) and total RNA was isolated using a 530

Direct-zol RNA MiniPrep kit (Zymo Research). This total RNA was then used for Primer 531 ID and qRT-PCR. Proteinaceous debris in air spaces (none = 0, one instance = 1, > 1 instance = 2), (E) 550 alveolar septal thickening (< 2× mock thickness = 0, 2-4× mock thickness = 1, > 4× 551 mock thickness = 2). To obtain a lung injury score per field, the scores for A-E were 552 then put into the following formula, which contains multipliers that assign varying levels 553 of importance for each phenotype of the disease state.: score = [(20x A) + (14 x B) + (7 x C) + (7 x D) + (2 x E)]/100. The scores for the three fields per mouse were averaged 555 to obtain a final score ranging from 0 to and including 1. 

Cell death factor expression in HAE 

recent insights into emerging coronaviruses

Clinical Characteristics of 138 Hospitalized Patients With 2019 772 Novel Coronavirus-Infected Pneumonia

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. 775

Severe acute respiratory syndrome (SARS) in Singapore: clinical 777 features of index patient and initial contacts

Fatal swine acute diarrhoea syndrome caused by an HKU2-779 related coronavirus of bat origin

Molecular diversity of coronaviruses in bats

A SARS-like cluster of circulating bat coronaviruses 783 shows potential for human emergence

SARS-like WIV1-CoV poised for human emergence

Identification of a New Ribonucleoside Inhibitor of Ebola Virus 787 Replication

Compound That Induces a High Level of Mutations in the Viral Genome

Characterization of orally efficacious influenza drug with high 792 resistance barrier in ferrets and human airway epithelia

Small-Molecule Antiviral beta-d-N (4)-Hydroxycytidine 795 Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to 796 Resistance

Initiation, extension, and termination of RNA synthesis by a 798 paramyxovirus polymerase

Comparative therapeutic efficacy of remdesivir and 800 combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Broad-spectrum antiviral GS-5734 inhibits both epidemic 803 and zoonotic coronaviruses

Further Evidence for Bats as the Evolutionary Source of 805 Middle East Respiratory Syndrome Coronavirus

Bat origin of human coronaviruses

Evidence supporting a zoonotic origin of human coronavirus 809 strain NL63

Structure of the SARS-CoV nsp12 polymerase 811 bound to nsp7 and nsp8 co-factors

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-813 5734) Is Mediated by the Viral Polymerase and the Proofreading 814 Exoribonuclease

Synthetic recombinant bat SARS-like coronavirus is 816 infectious in cultured cells and in mice

A mouse model for Betacoronavirus subgroup 2c using a 819 bat coronavirus strain HKU5 variant

Orally Efficacious Broad-Spectrum Ribonucleoside Analog 821 Inhibitor of Influenza and Respiratory Syncytial Viruses

Template Sampling Depth and Greatly Reduces the Error Rate of Next-825

Generation Sequencing of HIV-1 Genomic RNA Populations

Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

New Metrics for 830 Evaluating Viral Respiratory Pathogenesis

A mouse model for MERS coronavirus-induced acute 832 respiratory distress syndrome

Emerging viral 834 diseases: confronting threats with new technologies

Coronavirus Infections-More Than Just 837 the Common Cold

Broad spectrum antiviral remdesivir inhibits human endemic 839 and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA 840 polymerase

Severe 2019-nCoV Remdesivir RCT (NCT04257656)

Characterization of beta-d-N(4)-Hydroxycytidine as a Novel 843 Inhibitor of Chikungunya Virus

Therapeutic efficacy of the small molecule GS-5734 against 845 Ebola virus in rhesus monkeys

GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, 847 and Paramyxoviruses

Viral Load Kinetics of MERS Coronavirus Infection

Clinical progression and viral load in a community outbreak of 851 coronavirus-associated SARS pneumonia: a prospective study

Middle East respiratory syndrome coronavirus (MERS-CoV) 854 causes transient lower respiratory tract infection in rhesus macaques

Replication of SARS coronavirus administered into the 857 respiratory tract of African Green, rhesus and cynomolgus monkeys

Coronaviruses -drug 860 discovery and therapeutic options

Coronaviruses lacking exoribonuclease activity are susceptible to lethal 863 mutagenesis: evidence for proofreading and potential therapeutics

Severe acute respiratory syndrome coronavirus infection of 866 human ciliated airway epithelia: role of ciliated cells in viral spread in the 867 conducting airways of the lungs

Reverse genetics with a full-length infectious cDNA of the 869

Middle East respiratory syndrome coronavirus

Adaptive 872 evolution influences the infectious dose of MERS-CoV necessary to achieve 873 severe respiratory disease

A mouse-adapted SARS-coronavirus causes disease and 875 mortality in BALB/c mice

Well-877 differentiated human airway epithelial cell cultures

Accurate 880 sampling and deep sequencing of the HIV-1 protease gene using a Primer ID

Serial histopathological examination of the lungs of mice 883 infected with influenza A virus PR8 strain

An official American Thoracic Society workshop report: 885 features and measurements of experimental acute lung injury in animals

Memory CD8 T cells mediate severe immunopathology 888 following respiratory syncytial virus infection

Engineering a replication-competent, propagation-defective 890

Middle East respiratory syndrome coronavirus as a vaccine candidate

ConSurf 2016: an improved methodology to estimate and 893 visualize evolutionary conservation in macromolecules